$30M upfront + $50M upon approval + 9% royalty Gilead assumes all trial costs, regulatory, distribution, etc. Brilacidin for COVID remains a combo-only treatment.
Would be a tremendous deal for us. Stock price would shoot over $1 on the announcement.